Casdatifan targets a transcription factor that binds with other proteins to switch off the body’s anti-inflammatory mechanisms, empowering genes that promote tumor growth in clear cell renal cell ...

The "Analgesics - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.The global ...

In addition to AVT06, which is a biosimilar candidate for Eylea ® (aflibercept) 2 mg, Alvotech is currently also developing ...

In the realm of men’s health, maintaining optimal vitality, stamina, and confidence is paramount. With the increasing pace of ...

Given Yakult’s record in attaining 2%-4% penetration in many emerging markets, upside potential in the areas outside three first-tier cities—currently representing 80% of Yakult’s target population in ...

NEW YORK, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a ...

Ashi Anand, Founder & CEO of IME Capital, suggests cautious investing as further market declines are possible despite India's ...

So far, five biosimilars that reference Eylea 2 mg have been approved by the FDA. Alvotech/Teva expect to regulatory approval for its biosimilar to be completed in the fourth quarter of 2025.

Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with additional cardiovascular risk factors, can significantly reduce heart ...

LAS VEGAS, NV / ACCESS Newswire / / ALT5 Sigma Corporation (NASDAQ:ALTS), a leading fintech innovator specializing in blockchain-powered solutions, today announced that the Official $TRUMP Coin has ...

Scientists have discovered an antibody treatment that may help prevent both muscle loss and bone density loss in people using ...

Solid said that the first patients to receive its Duchenne gene therapy all produced high levels of the target protein, an ...